-
"We have shown for the first time that immediate treatment after a first clinical demyelinating event suggestive of MS can reduce the early neurological damage, which may ultimately delay the development of the debilitating sequelae that characterize adv
-
Patients given daclizumab every two weeks had a significantly reduced lesions at week 24 compared with those in the placebo group.
-
The TERMS (Tovaxin for Early Relapsing Multiple Sclerosis) study is testing Tovaxin, an autologous T-Cell vaccination in patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
-
Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
-
The MS Society is 'bitterly disappointed' after the Scottish Medicines Consortium (SMC) advised health professionals not to prescribe Tysabri - the only drug licensed for multiple sclerosis (MS) that has shown significant promise in slowing the progress
-
AVONEX(R) (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be stored at room temperature (up to 77 degrees F or 25 degrees C) in its prefilled formulation for a period up to 7 days.
-
TYSABRI® is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations.
-
Early and ongoing treatment with interferon beta-1a can provide lasting benefits to patients with relapsing-remitting multiple sclerosis (MS), according to a report in the journal Neurology
-
Generic drug maker Teva Pharmaceutical Industries Ltd. said Monday new data from a study of its multiple sclerosis drug reinforce previous information that the treatment reduces relapses of symptoms and may slow tissue damage associated with the disease.
-
Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
-
At 48 weeks into a 96 week phase 3b trial, a new formulation of Rebif (interferon beta-1a), researchers report that 44 mcg given subcutaneously 3 time a weeks significantly improves tolerability and reduces antibody formation compared with historical 48-w
-
A new study showed that very active patients who received COPAXONE(R) (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (Pless than0.0001) compared to those
-
Schering AG Germany, announced today results from the subgroup analysis of the BENEFIT* study which showed that Betaferon® (interferon beta-1b) 250mcg treatment reduced the risk of developing clinically definite MS (CDMS) consistent
-
Biogen Idec (NASDAQ: BIIB) announced findings today from the Global Adherence Project (GAP) that demonstrated patients taking AVONEX(R) (interferon beta-1a), the most prescribed multiple sclerosis (MS) treatment worldwide, adhered to treatment more than p
-
The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions observed on serial MRI scans of the brain at weeks 12, 16, 20 and 24 in the Rituxan-treated group compared to placebo
